Top Markets
#1 MowCat MowCat +48.73%
#2 Velvet Velvet +24.78%
#3 Fake World Assets Fake World Assets +24.13%
#4 Bitway Bitway +22.50%
#5 aPriori aPriori +21.20%
#6 OVERTAKE OVERTAKE +20.01%
#7 Biconomy Biconomy +17.12%
#8 Derive Derive +14.68%
#9 Audiera Audiera +13.62%
#10 Zerebro Zerebro +12.49%
Coin of the day
MowCat MowCat
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Nicox S.A. Nicox S.A.

Nicox S.A.

COX
Kedudukan dalam Saham #34243
Nicox S.A. is an ophthalmology enterprise operating both within France and... Nicox S.A. is an ophthalmology enterprise operating both within France and globally, focused on developing therapies to safeguard vision and enhance overall eye health. Its leading investigational drug, NCX 470, an innovative nitric oxide-donating prostaglandin analog designed to decrease intraocular pressure in individuals with open-angle glaucoma or ocular hypertension, is currently undergoing Phase 3 clinical trials. Furthermore, the company is progressing NCX 4251, a specialized fluticasone formulation, through a Phase 2b clinical trial for the management of acute exacerbations of blepharitis, as well as NCX 1728. Nicox also provides VYZULTA, a latanoprostene bunod ophthalmic solution for treating open-angle glaucoma or ocular hypertension, and ZERVIATE, a cetirizine ophthalmic solution to relieve ocular itching related to allergic conjunctivitis. The company, established in 1996, has its main office situated in Valbonne, France.
Harga Saham
$0.6379482
Disegerakkan terakhir: 2023-05-22
Modal Pasaran
$5.98M
Perubahan (1 hari)
-0.44%
Perubahan (1 tahun)
0.00%
Negara
FR
Perdagangan Nicox S.A. (COX)

Kategori

Healthcare
Pendapatan untuk Nicox S.A. (COX)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Nicox S.A., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Nicox S.A. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE